Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
Protara Therapeutics reported positive 12-month data from the Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve NMIBC patients. The data showed a 55% complete response rate at the 12-month landmark, with 91.7% of responders maintaining their response from nine to 12 months.
Key figures
- Drug Name
- TARA-002
- Phase Of Trial
- Phase 2
- Cr rate 6 month
- 66.7%
- Cr rate 12 month
- 55.0%
- Cr rate any time
- 72.4%
- Maintained cr 9 to 12m
- 91.7%
- Total patients bcgn naive
- 31
- Evaluable patients 6 month
- 27
- Evaluable patients 12 month
- 20
- Km probability maintain cr 6m
- 73.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.